- September 28, 2016
New startup will leverage a method for simultaneously sequencing and mapping thousands of RNAs within cells and tissues to advance development of diagnostics and discover new drug targets
- December 16, 2015
Two emerging life-science ventures draw a crowd and elicit substantive expert feedback at “Guppy Tank” event.
- September 16, 2014
Professors Dan Finley and Randy King are poised to change the future for those who suffer from neurodegenerative diseases. With the help of OTD’s Biomedical Accelerator, they were able to build on this foundation and advance the frontiers of science and healthcare.
- July 15, 2013
Paris (France), 15 July 2013 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School (Harvard).Under the terms of the agreement, Ipsen will fund Harvard research for at least three years with the aim to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of serious neurologic diseases.